Seaport Therapeutics (SPTX) Corporate presentation summary

Market opportunity and unmet need

• Over 1 billion people globally live with mental illness, with depression and anxiety highly comorbid and disabling.

• Major depressive disorder (MDD) and anxiety disorders affect hundreds of millions worldwide, with high suicide risk in MDD.

• Current neuropsychiatric medications have modest efficacy, slow onset, and unfavorable side effects, leaving significant unmet needs.

Leadership and proven track record

• Leadership team includes founders and executives with experience in successful neuropsychiatric drug development and major biotech exits.

• Team members have led development and commercialization of drugs like Zyprexa, Cymbalta, and LATUDA.

• Previous success with Karuna Therapeutics, acquired for $14B, demonstrates ability to deliver value for patients and shareholders.

Glyph™ platform and scientific innovation

• Glyph™ platform enables oral delivery of drugs previously limited by first-pass metabolism, improving bioavailability and reducing hepatotoxicity.

• Proprietary prodrug chemistry leverages lymphatic transport to bypass the liver, generating new intellectual property.

• Platform validated across over 24 small molecules and supported by peer-reviewed research.